Another limitation of this study was a sample size of 31 enrolled patients as compared with 107 patients with FGFR2 rearrangements included in FIGHT‐202,26 because patient accrual in a single country usually takes a long time for rare cancers. The gene discussed is FGFR2; the disease is cancer.